Newsroom

Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026

28.05.2026

The trial is led by Amir A. Jazeri, MD, Vice Chair for Clinical Research and the Director of the Gynecologic Cancer Immunotherapy Program in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center.

28.04.2026

Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer

04.03.2026

Theolytics Awarded €8 million in Horizon Europe 2025 Grant Funding to Advance Phase 2 Study of THEO-260 in Ovarian Cancer

13.10.2025

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025 in Berlin

07.10.2025

Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

17.12.2024

Theolytics Appoints David Apelian MD, PhD, MBA as CEO

19.11.2024

Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer

02.09.2024

Theolytics Awarded Significant £2M Transforming Cancer Therapeutics Grant from Innovate UK

17.04.2024

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

21.03.2024

Mike Grey appointed Executive Chair of Theolytics’ Board of Directors

28.11.2023

Theolytics presents data at ESMO on its lead program being developed for Ovarian Cancer

09.06.2023

Theolytics presents data on THEO-260 at ASCO and EHA

31.05.2022

Theolytics' £1M project with InnovateUK to develop a novel therapy

01.07.2021

Theolytics is taking part in the BIA Research Relay 2021

06.11.2020

Theolytics awarded Innovate UK boost to help combat ovarian cancer

07.01.2020

Theolytics raises $6.8 million Series A round co-led by Epidarex Capital and Taiho Ventures

Upcoming Events

We’ll be attending these events over the coming months.

23rd - 24th September 2026

LSX Congress USA (LSX USA)

Boston, MA, USA

19th - 20th October 2026

3rd Annual Oncology Venture, Innovation & Partnering Summit

Cambridge, MA, USA

4th - 8th November 2026

SITC 2026

Phoenix, Texas, USA

16th - 17th November 2026

LSX Investival Showcase

London, UK